Integra LifeSciences (NASDAQ:IART) Stock Rating Lowered by Oppenheimer

Oppenheimer downgraded shares of Integra LifeSciences (NASDAQ:IART) from an outperform rating to a market perform rating in a research note released on Tuesday, MarketBeat Ratings reports.

Several other analysts have also recently issued reports on IART. Truist Financial dropped their price objective on shares of Integra LifeSciences from $46.00 to $41.00 and set a hold rating for the company in a research note on Friday, March 1st. JMP Securities reduced their price target on Integra LifeSciences from $55.00 to $49.00 and set a market outperform rating on the stock in a report on Thursday, February 29th. Wells Fargo & Company cut shares of Integra LifeSciences from an overweight rating to an equal weight rating and cut their price objective for the stock from $45.00 to $25.00 in a research report on Tuesday. Citigroup upgraded shares of Integra LifeSciences from a sell rating to a neutral rating and set a $38.00 target price on the stock in a report on Wednesday, April 3rd. Finally, StockNews.com downgraded shares of Integra LifeSciences from a buy rating to a hold rating in a report on Tuesday, April 30th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of Hold and an average target price of $36.80.

Integra LifeSciences Stock Up 8.4 %

Shares of NASDAQ IART opened at $25.08 on Tuesday. The firm has a market cap of $1.97 billion, a price-to-earnings ratio of 30.22, a price-to-earnings-growth ratio of 0.87 and a beta of 1.17. The company’s 50-day simple moving average is $32.95 and its 200-day simple moving average is $38.24. The company has a quick ratio of 2.18, a current ratio of 3.45 and a debt-to-equity ratio of 0.94. Integra LifeSciences has a 52-week low of $22.36 and a 52-week high of $51.12.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Monday, May 6th. The life sciences company reported $0.55 EPS for the quarter, hitting the consensus estimate of $0.55. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The firm had revenue of $368.90 million during the quarter, compared to analysts’ expectations of $361.96 million. During the same period in the previous year, the business earned $0.74 earnings per share. The firm’s revenue for the quarter was down 3.2% on a year-over-year basis. Equities analysts predict that Integra LifeSciences will post 3.19 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of IART. Vanguard Group Inc. increased its stake in Integra LifeSciences by 1.0% during the third quarter. Vanguard Group Inc. now owns 7,159,854 shares of the life sciences company’s stock worth $273,435,000 after purchasing an additional 72,294 shares during the period. Capital Research Global Investors grew its holdings in shares of Integra LifeSciences by 40.1% in the fourth quarter. Capital Research Global Investors now owns 4,297,326 shares of the life sciences company’s stock valued at $187,149,000 after purchasing an additional 1,228,996 shares in the last quarter. Cooke & Bieler LP increased its stake in Integra LifeSciences by 4.4% during the 4th quarter. Cooke & Bieler LP now owns 2,834,604 shares of the life sciences company’s stock worth $123,447,000 after buying an additional 120,410 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Integra LifeSciences by 4.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,615,112 shares of the life sciences company’s stock worth $70,340,000 after buying an additional 63,323 shares in the last quarter. Finally, Victory Capital Management Inc. boosted its position in Integra LifeSciences by 19.5% in the 3rd quarter. Victory Capital Management Inc. now owns 1,465,115 shares of the life sciences company’s stock valued at $55,953,000 after buying an additional 238,816 shares during the period. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.